Zacks Rating on Celgene Corporation (CELG)

Celgene Corporation (CELG) has an average broker rating of 1.35, which is interpreted as a Strong Buy, as rated by 17 equity analysts. Nonetheless, 14 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 3 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Celgene Corporation (CELG) : The consensus price target for Celgene Corporation (CELG) is $141.79 for the short term with a standard deviation of $12.26. The most optimist securities analyst among the 14 who monitor the stock believes that the stock can reach $162, however, the pessimist price target for the company is $120.


Shares of Celgene Corporation rose by 1.64% in the last five trading days and 5.63% for the last 4 weeks. Celgene Corporation is up 9.94% in the last 3-month period. Year-to-Date the stock performance stands at -4.8%. Celgene Corporation (NASDAQ:CELG): On Tuesdays trading session , Opening price of the stock was $114.49 with an intraday high of $115.52. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $113.92. However, the stock managed to close at $114.01, a loss of 0.17% for the day. On the previous day, the stock had closed at $114.2. The total traded volume of the day was 2,303,075 shares.

Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.